Enhanced Anti-Inflammatory Effect of the Combination of Lactiplantibacillus plantarum LS/07 with Methotrexate Compared to Their Monotherapies Studied in Experimental Arthritis.
Katarína PružinskáLukáš SlovákFrantišek DráfiSilvester PoništIvo JuránekMartin ChrastinaKarol ŠvíkLadislav StrojnýĽuboš AmbroKatarína BauerováPublished in: Molecules (Basel, Switzerland) (2022)
The gut microbiome (GM) of rheumatic arthritis (RA) patients is often altered in composition and function. Moreover, methotrexate (MTX), one of the most frequently used disease-modifying antirheumatic drugs, is known to negatively affect GM composition. The modulation of immune system activity is one of the therapeutic benefits of probiotics. The aim of the current investigation was to determine the impact of MTX therapy combined with one of the Lactobacillus strains, Lactoplantibacillus plantarum LS/07 (LB), on adjuvant arthritis (AA) in rats. Methods focused on biometric and inflammatory parameters in AA, particularly on plasmatic levels of IL-17A, MMP-9, and MCP-1, and the activities of gamma-glutamyl transferase in the spleen and joints were applied. Enhancing the effect of MTX, LB positively influenced all biometric and inflammatory parameters. The findings of the present study may be of help in proposing novel therapeutic strategies for RA patients.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- escherichia coli
- prognostic factors
- anti inflammatory
- peritoneal dialysis
- high dose
- stem cells
- patient reported
- interstitial lung disease
- ankylosing spondylitis
- idiopathic pulmonary fibrosis
- solid state